HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aesthetic Medicine

733.427

+5.8520.80%

Number of Gainers:3

Number of Losers:5

Number of Flat:5

PE:- -

High:743.242

Open:723.690

Low:709.153

Close:727.575

Loading ...

Sihuan Pharmaceutical Unit Gets China Nod for Facial Filler

MT Newswires Live

BRIEF-Sihuan Pharma Obtains Approval For Injectable Polycaprolactone Microsphere Facial Filler

Sihuan Pharma - Injectable Polycaprolactone Microsphere Facial Filler Obtained Registration Approval From Nmpa

THOMSON REUTERS

Sihuan Pharmaceutical Increases Investment in Medical Aesthetics Unit; Shares Rise 5%

MT Newswires Live

BRIEF-Sihuan Pharma Says Meiyan Space, Others To Increase Registered Capital Of Meifu Co

Shanghai Fosun Pharmaceutical Raises Stake in United Health Insurance; Shares Rise

MT Newswires Live

Sihuan Pharma - Meiyan Space, Hainan Temmei, and Meifu Co to Increase Registered Capital of Meifu Co From RMB1 Mln to RMB50 Mln

THOMSON REUTERS

BRIEF-Sihuan Pharmaceutical Holdings Group FY Gross Profit RMB 1,241.7 Million

Sihuan Pharmaceutical Holdings Group FY Gross Margin 65.3%

THOMSON REUTERS

Modern Dental Group Announces 2024 Annual Results:Profits Rise and Dividend Payout Raised to 40%; Well Diversified Global Operations and Digital Transformation Delivered Solid Results

THOMSON REUTERS

BRIEF-Modern Dental Says Chan Kwun Fung, Executive Director Will Relinquish His Role As A Non-Executive Director

BRIEF-Modern Dental Group Posts FY Gross Margin Of 53.5%

Modern Dental - Chan Kwun Fung, Executive Director Will Relinquish His Role as a Non-Executive Director

THOMSON REUTERS

Modern Dental Group FY Adjusted Ebitda Margin 22%

THOMSON REUTERS

Modern Dental Group Ltd - FY Net Profit for Year HK$406.9 Mln

THOMSON REUTERS

3SBio's 2024 Profit Jumps 35%

MT Newswires Live

Fosun Pharmaceutical-Owned Gland Pharma to Invest 1.6 Billion Yuan in Indian Mutual Funds, Bonds

MT Newswires Live

Press Release: Fosun Pharma Announces 2024 Annual Results

BRIEF-3SBIO Announces Final Dividend Of HKD25 Cents Per Share

3SBio FY Adjusted Ebitda RMB 3,402.3 Million

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1593/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"Aesthetic Medicine","latestPrice":733.4272,"timestamp":1743667695025,"preClose":727.575,"halted":0,"volume":137399054,"delay":0,"changeRate":0.008043,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":5.852173,"latestTime":"04-03 16:00:00","open":723.6904,"high":743.2424,"low":709.1533,"amount":1046478655,"amplitude":0.046853,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743989400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1743643800000,1743652800000],[1743656400000,1743667200000]],"pbRate":1.310598,"peRate":20.150476,"turnoverRate":0.006731,"increases":4,"decrements":5,"flats":4,"marketCap":126739730408,"floatMarketCap":88228815784},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":743.2424,"amplitude":0.046853,"preClose":727.575,"low":709.1533,"pbRate":"1.310598","latestPrice":733.4272,"volume":137399054,"delay":0,"open":723.6904,"prevYearClose":571.87146,"prevWeekClose":701.326,"prevMonthClose":677.607,"prevQuarterClose":677.607,"fiveDayClose":693.85,"twentyDayClose":617.971,"sixtyDayClose":546.164,"secType":"PLATE","market":"HK","turnoverRate":0.006731,"peRate":20.150476,"marketCap":126739730408,"floatMarketCap":88228815784,"timestamp":1743667695025,"nameCN":"Aesthetic Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":3,"down":5,"flat":5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524402298","title":"Sihuan Pharmaceutical Unit Gets China Nod for Facial Filler","url":"https://stock-news.laohu8.com/highlight/detail?id=2524402298","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524402298?lang=en_us&edition=fundamental","pubTime":"2025-04-03 14:48","pubTimestamp":1743662933,"startTime":"0","endTime":"0","summary":"China's medical products regulator granted Sihuan Pharmaceutical  subsidiary Meiyan Space Biological Technology  class 3 medical device approval for its injectable polycaprolactone microsphere facial filler.The filler is a regenerative material that helps address facial contour deficiencies and corrects wrinkles in between the nose and lips, according to a Wednesday filing with the Hong Kong bourse.Shares in the aesthetic product company fell 3% during afternoon trading on Thursday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","00460","BK1191","BK1600","BK1515"],"gpt_icon":0},{"id":"2524135418","title":"BRIEF-Sihuan Pharma Obtains Approval For Injectable Polycaprolactone Microsphere Facial Filler","url":"https://stock-news.laohu8.com/highlight/detail?id=2524135418","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524135418?lang=en_us&edition=fundamental","pubTime":"2025-04-02 23:23","pubTimestamp":1743607437,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharma Obtains Approval For Injectable Polycaprolactone Microsphere Facial Filler April 2  - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:INJECTABLE POLYCAPROLACTONE MICROSPHERE FACIAL FILLER OBTAINED REGISTRATION APPROVAL FROM NMPAFurther company coverage: 0460.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0S6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","BK1515","BK1191","BK1593","00460"],"gpt_icon":0},{"id":"2524650254","title":"Sihuan Pharma -  Injectable Polycaprolactone Microsphere Facial Filler Obtained Registration Approval From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2524650254","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524650254?lang=en_us&edition=fundamental","pubTime":"2025-04-02 18:57","pubTimestamp":1743591466,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0S6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1600","00460","BK1593","BK1515"],"gpt_icon":0},{"id":"2524157562","title":"Sihuan Pharmaceutical Increases Investment in Medical Aesthetics Unit; Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524157562","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524157562?lang=en_us&edition=fundamental","pubTime":"2025-04-01 16:03","pubTimestamp":1743494583,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group  made a capital increase in Hainan Meifu Medical Device to increase its presence in the aesthetics market, according to a Tuesday filing with the Hong Kong bourse.Meiyan Space, a non-wholly owned subsidiary of Sihuan, will invest 25.5 million yuan, while Hainan Temmei, a connected party but not a subsidiary of the company, will invest 23.5 million yuan.This move raised Meifu's registered capital to 50 million yuan, with Meiyan holding 51% and Hainan Temmei 49%.The pharmaceutical company's shares were 5% higher in recent trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","00460","BK1191","BK1600","BK1515"],"gpt_icon":0},{"id":"2524130214","title":"BRIEF-Sihuan Pharma Says Meiyan Space, Others To Increase Registered Capital Of Meifu Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2524130214","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524130214?lang=en_us&edition=fundamental","pubTime":"2025-04-01 14:04","pubTimestamp":1743487448,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharma Says Meiyan Space, Others To Increase Registered Capital Of Meifu CoApril 1  - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:MEIYAN SPACE, HAINAN TEMMEI, AND MEIFU CO TO INCREASE REGISTERED CAPITAL OF MEIFU CO FROM RMB1 MILLION TO RMB50 MILLIONUPON COMPLETION, SHARES OF MEIFU CO WILL BE OWNED AS TO 51% AND 49% BY MEIYAN SPACE AND HAINAN TEMMEIFurther company coverage: 0460.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF003:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1515","00460","BK1600","BK1191"],"gpt_icon":0},{"id":"2524137478","title":"Shanghai Fosun Pharmaceutical Raises Stake in United Health Insurance; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2524137478","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524137478?lang=en_us&edition=fundamental","pubTime":"2025-04-01 13:46","pubTimestamp":1743486361,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Raises Stake in United Health Insurance; Shares RiseShanghai Fosun Pharmaceutical   signed a Share Subscription Agreement with IFC and ADB to invest 270 million yuan each in United Health Insurance, according to a Monday filing with the Hong Kong bourse.The deal will increase Fosun Pharma's stake in the insurer from 14.00% to 20.05%. The capital infusion, totaling 810 million yuan, will support the company's expansion. The transaction does not require the approval of independent shareholders.Fosun Pharma views this investment as a strategic move to enhance its presence in China's rapidly growing health insurance sector.The pharmaceuticals shares were up 6% in Hong Kong and 4% in Shanghai in recent trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK1230","BK0175","02196","BK0028","UBCP","BK1191","BK4211","BK0012","00656","BK1515","600196","BK0183","BK1593","BK0096","BK0187","BK0196","BK0239","BK0188"],"gpt_icon":0},{"id":"2524254139","title":"Sihuan Pharma -  Meiyan Space, Hainan Temmei, and Meifu Co to Increase Registered Capital of Meifu Co From RMB1 Mln to RMB50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2524254139","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524254139?lang=en_us&edition=fundamental","pubTime":"2025-04-01 12:23","pubTimestamp":1743481424,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF003:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1600","00460","BK1593","BK1191"],"gpt_icon":0},{"id":"2522599861","title":"BRIEF-Sihuan Pharmaceutical Holdings Group FY Gross Profit RMB 1,241.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522599861","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522599861?lang=en_us&edition=fundamental","pubTime":"2025-03-28 12:22","pubTimestamp":1743135732,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharmaceutical Holdings Group FY Gross Profit RMB 1,241.7 MillionMarch 28  - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:FY REVENUE RMB 1,901.1 MILLIONFY GROSS PROFIT RMB 1,241.7 MILLIONFY GROSS MARGIN 65.3%FY PRETAX PROFIT RMB -428.3 MILLIONFurther company coverage: 0460.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nPLXF4172E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1593","00460","BK1600","BK1191"],"gpt_icon":0},{"id":"2522259514","title":"Sihuan Pharmaceutical Holdings Group FY Gross Margin 65.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522259514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522259514?lang=en_us&edition=fundamental","pubTime":"2025-03-28 12:01","pubTimestamp":1743134468,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nPLXF4172E:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1593","00460","BK1600","BK1515"],"gpt_icon":0},{"id":"2522569077","title":"Modern Dental Group Announces 2024 Annual Results:Profits Rise and Dividend Payout Raised to 40%; Well Diversified Global Operations and Digital Transformation Delivered Solid Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522569077","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522569077?lang=en_us&edition=fundamental","pubTime":"2025-03-28 10:09","pubTimestamp":1743127787,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUC7NB58L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03600","BK1583","BK1100","BK1593"],"gpt_icon":0},{"id":"2522583709","title":"BRIEF-Modern Dental Says Chan Kwun Fung, Executive Director Will Relinquish His Role As A Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2522583709","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522583709?lang=en_us&edition=fundamental","pubTime":"2025-03-27 23:26","pubTimestamp":1743089176,"startTime":"0","endTime":"0","summary":"BRIEF-Modern Dental Says Chan Kwun Fung, Executive Director Will Relinquish His Role As A Non-Executive DirectorMarch 27  - Modern Dental Group Ltd 3600.HK:CHAN KWUN FUNG, EXECUTIVE DIRECTOR WILL RELINQUISH HIS ROLE AS A NON-EXECUTIVE DIRECTORFurther company coverage: 3600.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA1GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1593","BK1100","03600"],"gpt_icon":0},{"id":"2522588227","title":"BRIEF-Modern Dental Group Posts FY Gross Margin Of 53.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522588227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522588227?lang=en_us&edition=fundamental","pubTime":"2025-03-27 23:10","pubTimestamp":1743088212,"startTime":"0","endTime":"0","summary":"BRIEF-Modern Dental Group Posts FY Gross Margin Of 53.5%March 27  - Modern Dental Group Ltd 3600.HK:FY GROSS MARGIN 53.5%FY ADJUSTED EBITDA MARGIN 22%FY  NET PROFIT FOR YEAR HK$406.9 MILLIONFY  REVENUE FOR YEAR HK$3.36 BILLIONFINAL DIVIDEND OF HK9.2 CENTS PER ORDINARY SHAREFurther company coverage: 3600.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX40D74C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1583","03600","BK1100"],"gpt_icon":0},{"id":"2522830477","title":"Modern Dental -  Chan Kwun Fung, Executive Director Will Relinquish His Role as a Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2522830477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522830477?lang=en_us&edition=fundamental","pubTime":"2025-03-27 22:13","pubTimestamp":1743084831,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA1GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","03600","BK1583","BK1100"],"gpt_icon":0},{"id":"2522769304","title":"Modern Dental Group FY Adjusted Ebitda Margin 22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522769304","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522769304?lang=en_us&edition=fundamental","pubTime":"2025-03-27 22:10","pubTimestamp":1743084602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX40D74C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","03600","BK1583","BK1100"],"gpt_icon":0},{"id":"2522047673","title":"Modern Dental Group Ltd - FY  Net Profit for Year HK$406.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2522047673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522047673?lang=en_us&edition=fundamental","pubTime":"2025-03-27 22:10","pubTimestamp":1743084602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX40D74C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03600","BK1100","BK1583","BK1593"],"gpt_icon":0},{"id":"2522384288","title":"3SBio's 2024 Profit Jumps 35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522384288","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522384288?lang=en_us&edition=fundamental","pubTime":"2025-03-26 17:19","pubTimestamp":1742980795,"startTime":"0","endTime":"0","summary":"3SBio's  attributable profit rose 35% to 2.09 billion yuan in 2024 from 1.55 billion yuan in 2023, according to a Tuesday filing with the Hong Kong bourse.Earnings per share at the biopharmaceutical company increased to 0.85 yuan from 0.62 yuan a year earlier.  Analysts at Visible Alpha estimated EPS per share at 0.83 yuan.Revenue grew 17% to 9.11 billion yuan from 7.82 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 8.90 billion yuan.The company declared a final dividend of HK$0.25 per share, payable Aug. 15 to shareholders on record as of July 25.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","01530","BK1583","BK1593"],"gpt_icon":0},{"id":"2522998528","title":"Fosun Pharmaceutical-Owned Gland Pharma to Invest 1.6 Billion Yuan in Indian Mutual Funds, Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2522998528","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522998528?lang=en_us&edition=fundamental","pubTime":"2025-03-26 13:25","pubTimestamp":1742966702,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  subsidiary Gland Pharma  is planning to invest up to 20 billion Indian rupees  in Indian mutual funds and government or corporate bonds.Investments will be in low-risk mutual funds and bond products in accordance with the principle of strict risk control, according to a Tuesday filing with the Shanghai bourse.The authorization is valid until March 31, 2027.Fosun Pharma's shares fell nearly 2% in Hong Kong and almost 1% in Shanghai recently.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0187","02196","BK0183","BK1515","BK0196","BK1191","BK0175","BK0096","BK1593","600196","BK0012","BK1230","BK0028","00656","BK0239","BK0060"],"gpt_icon":0},{"id":"2522386319","title":"Press Release: Fosun Pharma Announces 2024 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522386319","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522386319?lang=en_us&edition=fundamental","pubTime":"2025-03-26 10:29","pubTimestamp":1742956140,"startTime":"0","endTime":"0","summary":"Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY. SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai Fosun Pharmaceutical  Co., Ltd. , a leading global pharmaceutical and healthcare company driven by innovation, announced its annual results for the year ended 31 December 2024 .During the Reporting Period, Fosun Pharma continuously optimized its innovative R&D system while maintaining stable R&D investment, focusing on key pipeline strengths and enhancing efficiency through system integration. In 2024, Fosun Pharma's total R&D expenditure amounted to RMB5.55 billion, with R&D expenses totaling RMB3.64 billion. The R&D expenditure in the pharmaceutical manufacturing segment amounted to RMB4.91 billion, accounting for 16.98% of pharmaceutical business revenue. There are over 80 major pipeline projects on innovative drugs and biosimilars . In addition, during the Reporting Period, the pharmaceutical manufacturing segment of Fosu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196","BK0012","BK4096","BK0060","BK1230","600196","00656","BK1515","BK0188","BK1593","PN","BK1191","BK0183","BK0187","BK0175","BK0196","BK0028","BK0239","BK0096"],"gpt_icon":0},{"id":"2522006008","title":"BRIEF-3SBIO Announces Final Dividend Of HKD25 Cents Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2522006008","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522006008?lang=en_us&edition=fundamental","pubTime":"2025-03-25 23:15","pubTimestamp":1742915757,"startTime":"0","endTime":"0","summary":"BRIEF-3SBIO Announces Final Dividend Of HKD25 Cents Per ShareMarch 25  - 3SBio Inc 1530.HK:FY BASIC EPS RMB 0.86FY GROSS MARGIN 86%FY REVENUE RMB 9,108 MILLIONFY GROSS PROFIT RMB 7,828.4 MILLIONFY EBITDA RMB 3,173.8 MILLIONFY ADJUSTED EBITDA RMB 3,402.3 MILLIONFINAL DIVIDEND OF HKD25 CENTS PER SHAREFurther company coverage: 1530.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nPLXDA38C0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK1593","01530"],"gpt_icon":0},{"id":"2522302440","title":"3SBio FY Adjusted Ebitda RMB 3,402.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522302440","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522302440?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:56","pubTimestamp":1742903775,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nPLXDA38C0:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1593","BK1583","01530"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26}]}}